Hypoxia-inducible factor-1α causes renal cyst expansion through calcium-activated chloride secretion

Journal of the American Society of Nephrology

Volumn 25, Issue 3, 2014, Pages 465-474

  Buchholz, Bjoern ^a   Schley, Gunnar ^a   Faria, Diana ^b   Kroening, Sven ^a   Willam, Carsten ^a   Schreiber, Rainer ^b   Klanke, Bernd ^a   Burzlaff, Nicolai ^a   Jantsch, Jonathan ^a   Kunzelmann, Karl ^b   Eckardt, Kai Uwe ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1 CHLORO 4 HYDROXYISOQUINOLINE 3 CARBOXAMIDO); CALCIUM ACTIVATED CHLORIDE CHANNEL; CRE RECOMBINASE; FORSKOLIN; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROLYL HYDROXYLASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STIMULATION; CHLORIDE CONDUCTANCE; CONTROLLED STUDY; CORRELATION ANALYSIS; EMBRYO; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; KIDNEY POLYCYSTIC DISEASE; MDCK CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; TUMOR GROWTH; TUMOR VOLUME; VON HIPPEL LINDAU DISEASE;

ANIMALS; ANOXIA; CHLORIDE CHANNELS; CHLORIDES; DOGS; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE, INBRED C57BL; POLYCYSTIC KIDNEY DISEASES;

EID: 84896839333     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013030209     Document Type: Article

References (54)

1. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301, 2007 (Pubitemid 46552051)
2. Terryn S, Ho A, Beauwens R, Devuyst O: Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease. Biochim Biophys Acta 1812: 1314-1321, 2011
3. Davidow CJ, Maser RL, Rome LA, Calvet JP, Grantham JJ: The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int 50: 208-218, 1996 (Pubitemid 26323715)
4. Magenheimer BS, St John PL, Isom KS, Abrahamson DR, De Lisle RC, Wallace DP, Maser RL, Grantham JJ, Calvet JP: Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na(+),K(+),2Cl(-) co-transporter-dependent cystic dilation. J Am Soc Nephrol 17: 3424-3437, 2006 (Pubitemid 44865285)
5. Yang B, Sonawane ND, Zhao D, Somlo S, Verkman AS: Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 1300-1310, 2008
6. Brill SR, Ross KE, Davidow CJ, Ye M, Grantham JJ, Caplan MJ: Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells. Proc Natl Acad Sci U S A 93: 10206-10211, 1996 (Pubitemid 26314600)
7. Buchholz B, Teschemacher B, Schley G, Schillers H, Eckardt KU: Formation of cysts by principal-like MDCK cells depends on the synergy of cAMP- and ATP-mediated fluid secretion. J Mol Med (Berl) 89: 251-261, 2011
8. Turner CM, King BF, Srai KS, Unwin RJ: Antagonism of endogenous putative P2Y receptors reduces the growth of MDCK-derived cysts cultured in vitro. Am J Physiol Renal Physiol 292: F15-F25, 2007 (Pubitemid 46115928)
9. Schwiebert EM, Wallace DP, Braunstein GM, King SR, Peti-Peterdi J, Hanaoka K, Guggino WB, Guay-Woodford LM, Bell PD, Sullivan LP, Grantham JJ, Taylor AL: Autocrine extracellular purinergic signaling in epithelial cells derived from polycystic kidneys. Am J Physiol Renal Physiol 282: F763- F775, 2002
10. Bernhardt WM, Wiesener MS, Weidemann A, Schmitt R, Weichert W, Lechler P, Campean V, Ong AC, Willam C, Gretz N, Eckardt KU: Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol 170: 830-842, 2007 (Pubitemid 47339353)
11. Bello-Reuss E, Holubec K, Rajaraman S: Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int 60: 37-45, 2001 (Pubitemid 32587537)
12. Weidemann A, Johnson RS: Biology of HIF-1alpha. Cell Death Differ 15: 621-627, 2008
13. Semenza GL: Oxygen sensing, homeostasis, and disease. N Engl J Med 365: 537-547, 2011
14. Rosenberger C, Mandriota S, Jürgensen JS, Wiesener MS,Hörstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt KU: Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13: 1721-1732, 2002 (Pubitemid 34700596)
15. Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU: Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 18: 1462-1464, 2004 (Pubitemid 39561615)
16. Eckardt KU, Möllmann M, Neumann R, Brunkhorst R, Burger HU, Lonnemann G, Scholz H, Keusch G, Buchholz B, Frei U: Erythropoietin in polycystic kidneys. J Clin Invest 84: 1160-1166, 1989 (Pubitemid 19247586)
17. Semenza GL: HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51-56, 2010
18. Rankin EB, Tomaszewski JE, Haase VH: Renal cyst development inmice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 66: 2576-2583, 2006
19. Grantham JJ: Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 359: 1477-1485, 2008
20. Belibi F, Zafar I, Ravichandran K, Segvic AB, Jani A, Ljubanovic DG, Edelstein CL: Hypoxia-inducible factor-1α (HIF-1α) and autophagy in polycystic kidney disease (PKD). Am J Physiol Renal Physiol 300: F1235 - F1243, 2011
21. Anderson S, Oyama TT, Lindsley JN, Schutzer WE, Beard DR, Gattone VH 2nd, Komers R: 2-Hydroxyestradiol slows progression of experimental polycystic kidney disease. Am J Physiol Renal Physiol 302: F636-F645, 2012
22. Xia Y, Choi HK, Lee K: Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 49: 24-40, 2012
23. Raphael KL, Strait KA, Stricklett PK, Miller RL, Nelson RD, Piontek KB, Germino GG, Kohan DE: Inactivation of Pkd1 in principal cells causes a more severe cystic kidney disease than in intercalated cells. Kidney Int 75: 626-633, 2009
24. Wang Z, Schley G, Türkoglu G, Burzlaff N, Amann KU,Willam C, Eckardt KU, Bernhardt WM: The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior toischaemiabut is superior to EPO treatment. Nephrol Dial Transplant 27: 929-936, 2012
25. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, Memmert K, Naegeli HU, Petersen F, Eck MJ, Bair KW, Wood AW, Livingston DM: Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6: 33-43, 2004 (Pubitemid 38903160)
26. Schley G, Klanke B, Schödel J, Forstreuter F, Shukla D, Kurtz A, Amann K, Wiesener MS, Rosen S, Eckardt KU, Maxwell PH, Willam C: Hypoxiainducible transcription factors stabilization in the thick ascending limb protects against ischemic acute kidney injury. J Am Soc Nephrol 22: 2004-2015, 2011
27. Howie AJ, Smithson N, Rollason TP: Reconsideration of the development of the distal tubule of the human kidney. J Anat 183: 141-147, 1993 (Pubitemid 23272426)
28. Zimmerhackl LB, Rostasy K, Wiegele G, Rasenack A, Wilhelm C, Lohner M, Brandis M, Kinne RK: Tamm-Horsfall protein as a marker of tubular maturation. Pediatr Nephrol 10: 448-452, 1996 (Pubitemid 26261600)
29. Schwab K, Patterson LT, Aronow BJ, Luckas R, Liang HC, Potter SS: A catalogue of gene expression in the developing kidney. Kidney Int 64: 1588-1604, 2003 (Pubitemid 37323687)
30. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z: Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149: 2089-2094, 1996 (Pubitemid 26415225)
31. Li H, Findlay IA, Sheppard DN: The relationship between cell proliferation, Cl- secretion, and renal cyst growth: A study using CFTR inhibitors. Kidney Int 66: 1926-1938, 2004 (Pubitemid 41094317)
32. Paulmichl M, Lang F: Enhancement of intracellular calcium concentration by extracellular ATP and UTP in Madin Darby Canine Kidney cells. Biochem Biophys Res Commun 156: 1139-1143, 1988 (Pubitemid 18265704)
33. Grantham JJ, Mulamalla S, Swenson-Fields KI: Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 7: 556-566, 2011
34. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 2407-2418, 2012
35. Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU: Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363: 830-840, 2010
36. Knaup KX, Jozefowski K, Schmidt R, Bernhardt WM, Weidemann A, Juergensen JS, Warnecke C, Eckardt KU, Wiesener MS: Mutual regulation of hypoxia-inducible factor and mammalian target of rapamycin as a function of oxygen availability. Mol Cancer Res 7: 88- 98, 2009
37. Jantsch J, Wiese M, Schödel J, Castiglione K, Gläsner J, Kolbe S, Mole D, Schleicher U, Eckardt KU, Hensel M, Lang R, Bogdan C, Schnare M, Willam C: Toll-like receptor activation and hypoxia use distinct signaling pathways to stabilize hypoxia-inducible factor 1α (HIF1A) and result in differential HIF1A-dependent gene expression. J Leukoc Biol 90: 551-562, 2011
38. Ousingsawat J, Kongsuphol P, Schreiber R, Kunzelmann K: CFTR and TMEM16A are separate but functionally related Cl- channels. Cell Physiol Biochem 28: 715-724, 2011
39. Legendre C, Mooij MJ, Adams C, O'Gara F: Impaired expression of hypoxia-inducible factor-1α in cystic fibrosis airway epithelial cells - a role for HIF-1 in the pathophysiology of CF? J Cyst Fibros 10: 286-290, 2011
40. Zheng W, Kuhlicke J, Jäckel K, Eltzschig HK, Singh A, Sjöblom M, Riederer B, Weinhold C, Seidler U, Colgan SP, Karhausen J: Hypoxia inducible factor-1 (HIF-1)-mediated repression of cystic fibrosis transmembrane conductance regulator (CFTR) in the intestinal epithelium. FASEB J 23: 204-213, 2009
41. Sun H, Xia Y, Paudel O, Yang XR, Sham JS: Chronic hypoxia-induced upregulation of Ca2+-activated Cl- channel in pulmonary arterial myocytes: Amechanismcontributing to enhanced vasoreactivity. J Physiol 590: 3507-3521, 2012
42. Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, Song XW, Xu H, Mari S, Qian F, Pei Y, Musco G, Boletta A: Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 19: 488-493, 2013
43. Lutz MS, Burk RD: Primary cilium formation requires von Hippel-Lindau gene function in renal-derived cells. Cancer Res 66: 6903-6907, 2006 (Pubitemid 44197663)
44. Hildebrandt F, Benzing T, Katsanis N: Ciliopathies. N Engl J Med 364: 1533-1543, 2011
45. Esteban MA, Harten SK, Tran MG, Maxwell PH: Formation of primary cilia in the renal epitheliumis regulated by the von Hippel-Lindau tumor suppressor protein. J Am Soc Nephrol 17: 1801-1806, 2006 (Pubitemid 44036164)
46. Pollard PJ, Spencer-Dene B, Shukla D, Howarth K, Nye E, El-Bahrawy M, Deheragoda M, Joannou M, McDonald S, Martin A, Igarashi P, Varsani-Brown S, Rosewell I, Poulsom R, Maxwell P, Stamp GW, Tomlinson IP: Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 11: 311-319, 2007 (Pubitemid 46518311)
47. Adam J, Hatipoglu E, O 'Flaherty L, Ternette N, Sahgal N, Lockstone H, Baban D, Nye E, Stamp GW, Wolhuter K, Stevens M, Fischer R, Carmeliet P, Maxwell PH, Pugh CW, Frizzell N, Soga T, Kessler BM, El-Bahrawy M, Ratcliffe PJ, Pollard PJ: Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: Roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20: 524-537, 2011
48. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC: HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11: 335- 347, 2007
49. Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, Liu L, Liu Y, Yang C, Xu Y, Zhao S, Ye D, Xiong Y, Guan KL: Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 26: 1326-1338, 2012
50. Haase VH, Glickman JN, Socolovsky M, Jaenisch R: Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A 98: 1583-1588, 2001 (Pubitemid 32165542)
51. Ryan HE, Lo J, Johnson RS: HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015, 1998 (Pubitemid 28254373)
52. Buchholz B, Klanke B, Schley G, Bollag G, Tsai J, Kroening S, Yoshihara D, Wallace DP, Kraenzlin B, Gretz N, Hirth P, Eckardt KU, Bernhardt WM: The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis. Nephrol Dial Transplant 26: 3458-3465, 2011
53. Gekle M, Wünsch S, Oberleithner H, Silbernagl S: Characterization of two MDCK-cell subtypes as a model system to study principal cell and intercalated cell properties. Pflugers Arch 428: 157-162, 1994 (Pubitemid 24238860)
54. Hofmann J, Meier RJ, Mahnke A, Schatz V, Brackmann F, Trollmann R, Bogdan C, Liebsch G, Wang XD, Wolfbeis OS, Jantsch J: Ratiometric luminescence 2D in vivo imaging and monitoring of mouse skin oxygenation. Methods Appl Fluoresc 1:045002, 2013